AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20512069 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant gender (male)
Number of subjects: 100
Study 20512069 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant gender (female)
Number of subjects: 100
Study 19502534 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face
Number of subjects: 192
Study 19502534 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Internet and face-to-face
Number of subjects: 192
Study 19502534 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-only
Number of subjects: 192
Study 16492101 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretive bias training favoring threatening meanings
Number of subjects: 48
Study 16492101 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretive bias training favoring nonthreatening meanings
Number of subjects: 48
Study 15648983 — intervention group
Group type: EXPERIMENTAL
Intervention: OPEN
Number of subjects: 20
Study 15648983 — intervention group
Group type: EXPERIMENTAL
Intervention: RESERVOIR
Number of subjects: 20
Study 15648983 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 20
Study 11050693 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-10 (glyceryl trinitrate transdermal patch)
Number of subjects: 24
Study 11050693 — intervention group
Group type: COMPARATOR
Intervention: ND-10 (reference patch)
Number of subjects: 24
Study 11050693 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-10
Number of subjects: 24
Study 11050693 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-10 and ND-10
Number of subjects: 24
Study 9282973 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C-mannitol
Number of subjects: 135
Study 9282973 — intervention group
Group type: EXPERIMENTAL
Intervention: 51Cr-EDTA
Number of subjects: 135
Study 9282973 — intervention group
Group type: COMPARATOR
Intervention: Mannitol and 14C-mannitol
Number of subjects: 135
Study 9282973 — intervention group
Group type: COMPARATOR
Intervention: Lactulose and 51Cr-EDTA
Number of subjects: 135
Study 9282973 — intervention group
Group type: COMPARATOR
Intervention: Age effect on marker excretion
Number of subjects: 135
Study 9282973 — intervention group
Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 135
Study 8192291 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant study results
Number of subjects: 997
Study 8192291 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled trials
Number of subjects: 997
Study 8192291 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 997
Study 3576660 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable tablet formulation
Number of subjects: 10
Study 3576660 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine tablets
Number of subjects: 10
Study 30194275 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 0
Study 30194275 — intervention group
Group type: COMPARATOR
Intervention: Baricitinib 2 mg
Number of subjects: 0
Study 31158073 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic radical prostatectomy (RALP)
Number of subjects: 4003
Study 31158073 — intervention group
Group type: COMPARATOR
Intervention: Open retropubic radical prostatectomy (RRP)
Number of subjects: 4003
Study 27006510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (INT)
Number of subjects: 858
Study 27006510 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic treatment (Control)
Number of subjects: 858
Study 24736279 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of telmisartan
Number of subjects: 20332
Study 24736279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20332
Study 24736279 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 20332
Study 22344551 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg exenatide single dose
Number of subjects: 24
Study 22344551 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg exenatide single dose
Number of subjects: 24
Study 22344551 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg exenatide multiple doses
Number of subjects: 24
Study 22344551 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg exenatide multiple doses
Number of subjects: 24
Study 22344551 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events after 5 μg exenatide
Number of subjects: 24
Study 22344551 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events after 10 μg exenatide
Number of subjects: 24
Study 20843977 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysed patients (n=1585)
Number of subjects: 5817
Study 20843977 — intervention group
Group type: COMPARATOR
Intervention: Nonthrombolysed comparators (n=4232)
Number of subjects: 5817
Study 17681081 — intervention group
Group type: EXPERIMENTAL
Intervention: New dressing containing ceramide 2
Number of subjects: 37
Study 17681081 — intervention group
Group type: COMPARATOR
Intervention: No dressing (control)
Number of subjects: 37
Study 15117739 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin deletion allele
Number of subjects: 103
Study 10940515 — intervention group
Group type: EXPERIMENTAL
Intervention: Human natural leucocytic interferon (HNLI) applied locally at 2x10(6) U daily in pessaries for 21 days before surgery
Number of subjects: 27
Study 10940515 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment with HNLI)
Number of subjects: 27
Study 9263140 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose methotrexate (MTX) plus prednisone > or = 5 mg/day
Number of subjects: 133
Study 9263140 — intervention group
Group type: COMPARATOR
Intervention: Prednisone > or = 5 mg/day without MTX
Number of subjects: 133
Study 9263140 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose methotrexate (MTX)
Number of subjects: 133
Study 9263140 — intervention group
Group type: COMPARATOR
Intervention: Non-MTX treated patients
Number of subjects: 133
Study 8298553 — intervention group
Group type: EXPERIMENTAL
Intervention: CYA and methylprednisolone
Number of subjects: 25
Study 8298553 — intervention group
Group type: COMPARATOR
Intervention: CYA and methotrexate (MTX)
Number of subjects: 25
Study 3545273 — intervention group
Group type: EXPERIMENTAL
Intervention: (‐)‐adrenaline (0.06 microgram kg‐1 min‐1 for 90 min) + vehicle control (+)‐glucose infusion (60 min)
Number of subjects: 8
Study 3545273 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol (120 ng kg‐1 min‐1 for 30 min) + vehicle control (+)‐glucose infusion (90 min)
Number of subjects: 8
Study 3545273 — intervention group
Group type: EXPERIMENTAL
Intervention: (‐)‐adrenaline (0.06 microgram kg‐1 min‐1 for 90 min) + salbutamol (120 ng kg‐1 min‐1 for 30 min)
Number of subjects: 8
Study 3545273 — intervention group
Group type: COMPARATOR
Intervention: vehicle control (+)‐glucose infusion
Number of subjects: 8
Study 30662456 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS
Number of subjects: 24
Study 30662456 — intervention group
Group type: COMPARATOR
Intervention: HD-tDCS
Number of subjects: 24
Study 30662456 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham
Number of subjects: 24
Study 30662456 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24
Study 27657514 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 30
Study 27657514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24183837 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR 20-44 mL/min/1.73m(2)
Number of subjects: 1043
Study 24183837 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR > 60 mL/min/1.73m(2)
Number of subjects: 1043
Study 24183837 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR < 60 mL/min/1.73m(2)
Number of subjects: 1043
Study 24183837 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1043
Study 22526314 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorph form I of ST-246, 400 mg oral dose
Number of subjects: 0
Study 22526314 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorph form V of ST-246, 400 mg oral dose
Number of subjects: 0
Study 22526314 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorph form I of ST-246
Number of subjects: 0
Study 20525992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus gp100
Number of subjects: 676
Study 20525992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab alone
Number of subjects: 676
Study 20525992 — intervention group
Group type: COMPARATOR
Intervention: gp100 alone
Number of subjects: 676
Study 20525992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus gp100 vs Ipilimumab alone
Number of subjects: 676
Study 20525992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 676
Study 20525992 — intervention group
Group type: EXPERIMENTAL
Intervention: Study drugs
Number of subjects: 676
Study 17928878 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ combination therapy (300 mg/25 mg)
Number of subjects: 538
Study 17928878 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan monotherapy (300 mg)
Number of subjects: 538
Study 17928878 — intervention group
Group type: COMPARATOR
Intervention: HCTZ monotherapy (25 mg)
Number of subjects: 538
Study 17366796 — intervention group
Group type: EXPERIMENTAL
Intervention: NP plus endostatin
Number of subjects: 67
Study 17366796 — intervention group
Group type: COMPARATOR
Intervention: NP alone
Number of subjects: 67
Study 12514682 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage emergency department intervention (identification of high-risk patients and brief standardized nursing assessment)
Number of subjects: 4
Study 12514682 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage emergency department intervention
Number of subjects: 4
Study 12514682 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 4
Study 11707864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexarotene gel applied to target lesions
Number of subjects: 8
Study 11707864 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral bexarotene (300 mg/m²)
Number of subjects: 8
Study 11707864 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral bexarotene (6.5 mg/m²)
Number of subjects: 8
Study 11707864 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral bexarotene (300 mg/m²) for erythrodermic CTCL
Number of subjects: 8
Study 11707864 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (60 mg/day)
Number of subjects: 8
Study 8806288 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine
Number of subjects: 1221
Study 8806288 — intervention group
Group type: COMPARATOR
Intervention: Recombinant hepatitis B vaccine (comparator)
Number of subjects: 1221
Study 1321006 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-drug alternating combination treatment
Number of subjects: 0
Study 1321006 — intervention group
Group type: COMPARATOR
Intervention: Three-drug 'standard' combination treatment
Number of subjects: 0
Study 6148522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 20
Study 6148522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30902791 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D fortified snack bars (2000 mg Ca and 1000 IU vitamin D per day)
Number of subjects: 197
Study 30902791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 197
Study 30902791 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (Ca + D)
Number of subjects: 197
Study 29803270 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA24 (Automated Self-Administered 24-Hour Dietary Assessment Tool)
Number of subjects: 1081
Study 29803270 — intervention group
Group type: COMPARATOR
Intervention: AMPM (Interview-Administered Automated Multiple Pass Method)
Number of subjects: 1081
Study 25496523 — intervention group
Group type: EXPERIMENTAL
Intervention: Family School Success (FSS) program
Number of subjects: 139
Study 25496523 — intervention group
Group type: COMPARATOR
Intervention: CARE (active-control condition)
Number of subjects: 139
Study 24461162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 29
Study 24461162 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medication
Number of subjects: 29
Study 21902692 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg clopidogrel
Number of subjects: 200
Study 21902692 — intervention group
Group type: COMPARATOR
Intervention: 75 mg clopidogrel
Number of subjects: 200
Study 19190228 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosand filter (BSF) households
Number of subjects: 154
Study 19190228 — intervention group
Group type: COMPARATOR
Intervention: Control households
Number of subjects: 154
Study 17939615 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus of attention during postural control training
Number of subjects: 36
Study 17939615 — intervention group
Group type: COMPARATOR
Intervention: Internal focus of attention during postural control training
Number of subjects: 36
Study 12594145 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 60
Study 12594145 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 60
Study 10992842 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (2‐4% end‐tidal)
Number of subjects: 80
Study 10992842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.75‐1.5% end‐tidal)
Number of subjects: 80
Study 10992842 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.4‐0.8% end‐tidal)
Number of subjects: 80
Study 10992842 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion (75‐150 micrograms kg‐1 min‐1)
Number of subjects: 80
Study 8854471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed therapy with oral dexamethasone, 40 mg/day on 4 consecutive days each month for 6 months
Number of subjects: 12
Study 8854471 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone tablets
Number of subjects: 12
Study 1291184 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride mouthrinse (0.63% diluted to 0.1%)
Number of subjects: 55
Study 1291184 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 55
Study 1291184 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride mouthrinse
Number of subjects: 55
Study 6515368 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol 0.2 mg
Number of subjects: 12
Study 6515368 — intervention group
Group type: EXPERIMENTAL
Intervention: pirbuterol 0.4 mg
Number of subjects: 12
Study 31590640 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification based on sFlt-1/PlGF measurement and fullPIERS score, with recommendations to defer delivery for low-risk patients (sFlt-1/PlGF ≤38 AND fullPIERS< 10% risk).
Number of subjects: 750
Study 31590640 — intervention group
Group type: EXPERIMENTAL
Intervention: Active program of knowledge transfer about WHO recommendations for preeclampsia, including antenatal corticosteroids, antihypertensive therapy, and magnesium sulphate for seizure prophylaxis.
Number of subjects: 750
Study 28731266 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1,000 mg/day
Number of subjects: 20
Study 28731266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25805457 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-cathodal/right-anodal tDCS
Number of subjects: 0
Study 25805457 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-anodal/right-cathodal tDCS
Number of subjects: 0
Study 25805457 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 0
Study 23921600 — intervention group
Group type: EXPERIMENTAL
Intervention: Close monitoring of cerebral rStO2 and a treatment guideline to correct deviations in rStO2
Number of subjects: 0
Study 23921600 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical intervention algorithm based on cerebral perfusion-oxygenation changes
Number of subjects: 0
Study 23921600 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment guideline
Number of subjects: 0
Study 21320700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 76
Study 21320700 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 76
Study 19817986 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid compression ultrasound (CUS) examination
Number of subjects: 1002
Study 19817986 — intervention group
Group type: COMPARATOR
Intervention: Complete compression ultrasound (CUS) examination
Number of subjects: 1002
Study 16699457 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 328
Study 16699457 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 328
Study 15955540 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease group
Number of subjects: 65
Study 15955540 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly group
Number of subjects: 65
Study 10397375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400 mg loading dose followed by 200 mg once daily for up to 10 days)
Number of subjects: 1100
Study 10397375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 1100
Study 10397375 — intervention group
Group type: COMPARATOR
Intervention: Comparator drugs
Number of subjects: 1100
Study 8673784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartoon illustrations
Number of subjects: 234
Study 8673784 — intervention group
Group type: COMPARATOR
Intervention: Standard instructions without cartoons
Number of subjects: 234
Study 1512761 — intervention group
Group type: EXPERIMENTAL
Intervention: loxoprofen Na (prodrug)
Number of subjects: 29
Study 1512761 — intervention group
Group type: EXPERIMENTAL
Intervention: proglumetacin maleate (prodrug)
Number of subjects: 29
Study 1512761 — intervention group
Group type: COMPARATOR
Intervention: diclofenac Na (control)
Number of subjects: 29
Study 6419519 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil 40 mg
Number of subjects: 12
Study 6419519 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil 60 mg
Number of subjects: 12
Study 6419519 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil 100 mg
Number of subjects: 12
Study 6419519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6419519 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil (all doses)
Number of subjects: 12
Study 31093929 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin 338 administered 0 min before meal
Number of subjects: 44
Study 31093929 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin 338 administered 30 min before meal
Number of subjects: 44
Study 31093929 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin 338 administered 60 min before meal
Number of subjects: 44
Study 31093929 — intervention group
Group type: COMPARATOR
Intervention: Oral insulin 338 administered 360 min before meal
Number of subjects: 44
Study 29772035 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI implants (3M ESPE)
Number of subjects: 45
Study 29772035 — intervention group
Group type: EXPERIMENTAL
Intervention: SlimLine implants (Dentium)
Number of subjects: 45
Study 26468628 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (10 to 12 cmH2O) during inpatient cardiac rehabilitation
Number of subjects: 54
Study 26468628 — intervention group
Group type: COMPARATOR
Intervention: Standard CR without CPAP
Number of subjects: 54
Study 24844229 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported BMI corrected using gender and body shape perception
Number of subjects: 341
Study 24844229 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported BMI
Number of subjects: 341
Study 24844229 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression of reported BMI by gender and socioeconomic status
Number of subjects: 341
Study 22304443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic spectral imaging (DSI) colposcopy
Number of subjects: 177
Study 22304443 — intervention group
Group type: COMPARATOR
Intervention: Colposcopist impression
Number of subjects: 177
Study 20379055 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation factor IX
Number of subjects: 368
Study 20379055 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation factor XI
Number of subjects: 368
Study 20379055 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-2 antiplasmin
Number of subjects: 368
Study 20379055 — intervention group
Group type: COMPARATOR
Intervention: Classical risk factors adjustment
Number of subjects: 368
Study 20379055 — intervention group
Group type: COMPARATOR
Intervention: Factors II, V, X, XII, and plasminogen
Number of subjects: 368
Study 19281913 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (ARBs)
Number of subjects: 0
Study 16252734 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinmaitong
Number of subjects: 200
Study 16252734 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine
Number of subjects: 200
Study 14581665 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 45
Study 14581665 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 45
Study 14581665 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic carotid stenosis
Number of subjects: 45
Study 14581665 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic carotid stenosis
Number of subjects: 45
Study 10320236 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic homograft preserved in antibiotic solution at 4 degrees C
Number of subjects: 40
Study 10320236 — intervention group
Group type: EXPERIMENTAL
Intervention: Toronto stentless porcine valve
Number of subjects: 40
Study 10320236 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Freestyle stentless valve
Number of subjects: 40
Study 10320236 — intervention group
Group type: COMPARATOR
Intervention: Medtronic Intact aortic valve
Number of subjects: 40
Study 10320236 — intervention group
Group type: COMPARATOR
Intervention: Stented valve
Number of subjects: 40
Study 8708151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional IFN alfa-2a
Number of subjects: 45